Delving into the Latest Updates on NapaJen Pharma, Inc. with Synapse

概览

疾病领域	数量

肿瘤	2

排名前五的药物类型	数量

siRNA	2

排名前五的靶点	数量

TLR9(Toll样受体9)	2

关联

3

项与 NapaJen Pharma, Inc. 相关的药物

NJB-834

靶点

TLR9

作用机制

TLR9激动剂

在研机构

NapaJen Pharma, Inc.

原研机构

NapaJen Pharma, Inc.

在研适应症

实体瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Napa9-SPG

靶点

TLR9

作用机制

TLR9激动剂

在研机构

NapaJen Pharma, Inc.

原研机构

NapaJen Pharma, Inc.

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

NJA-730

靶点

CD40

作用机制

CD40抑制剂 [+2]

在研机构-

原研机构

NapaJen Pharma, Inc.

在研适应症-

非在研适应症

移植物抗宿主病

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

1

项与 NapaJen Pharma, Inc. 相关的临床试验

ACTRN12618001428257 / Completed临床1期

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NJA-730 in Healthy Volunteers

开始日期2018-10-16

申办/合作机构

NapaJen Pharma, Inc.

100 项与 NapaJen Pharma, Inc. 相关的临床结果

登录后查看更多信息

0 项与 NapaJen Pharma, Inc. 相关的专利（医药）

登录后查看更多信息

5

项与 NapaJen Pharma, Inc. 相关的文献（医药）

2024-03-25·Drug Delivery System

NapaJenからImmunohelixへ：新たな飛躍へ

作者: Arima, Kenji ; Sakurai, Kazuo

2015-03-01·Gene Therapy3区 · 医学

Permanent acceptance of mouse cardiac allografts with CD40 siRNA to induce regulatory myeloid cells by use of a novel polysaccharide siRNA delivery system

3区 · 医学

Article

作者: Ohno, N ; Zhang, Q ; Fujino, M ; Kobayashi, M ; Sakurai, K ; Hou, J ; Zou, H ; Mochizuki, S ; Xu, J ; Adachi, Y ; Ando, H ; Nonomura, N ; Uno, A ; Li, X-K ; Ichimaru, N ; Cai, S ; Higuchi, S ; Takahara, S

The CD40/CD154 co-stimulatory pathway is crucial in alloimmune response. We developed a novel small interfering RNA (siRNA) delivery system with a poly-dA extension at the 5'-end of the siRNA sense strand that was stably incorporated into 1,3-β-glucan (schizophyllan, SPG). This was captured and incorporated into dendritic cells (DCs) through its receptor, Dectin-1, specifically silencing CD40 genes (siCD40) to exert immunoregulatory activity. siCD40/SPG-treated CBA mice permanently accepted B10 fully mismatched cardiac allografts. Consistent with graft survival, the infiltration of CD4(+), CD8(+) T cells into the graft was lower, and that the numbers of CD40(low)CD11c(+) DCs cells and CD4(+)Foxp3(+)cells were increased in both the graft and in the recipient spleen. In addition, naive CBA recipients given an adoptive transfer of splenocytes from the primary recipients with siCD40/SPG accepted a heart graft from donor-type B10, but not third-party Balb/c mice. In conclusion, the treatment with siCD40/SPG targeting DCs could generate antigen-specific Tregs, resulting in the permanent acceptance of mouse cardiac allografts. These findings have important implications for clarifying the mechanism underlying the induction of tolerance in DCs, and also highlight the potential of immunomodulation and the feasibility of siRNA-based clinical therapy in the transplantation field.

2008-11-15·Bulletin of the Chemical Society of Japan

3′ Poly(dA)-Tailed Thrombin DNA Aptamer to Increase DNase-Resistance and Clotting Inhibitory Activity

作者: Takei, Yoshifumi ; Ando, Hironori ; Uno, Atsushi ; Koyama, Yoshikazu ; Satoh, Susumu ; Shimada, Naohiko ; Sakurai, Kazuo ; Takeda, Yoichi ; Uehara, Shuichiro

AbstractAptamers are an attractive candidate for a molecular-targeted drug since they can show ability to precisely recognize proteins with a large affinity similar to antibodies. A drawback of aptamers is that they can be easily degraded under biological conditions by DNase (or RNase). In this study, we attached poly(dA) tail to the 3′ end of thrombin DNA aptamer and found that its survival time in human plasma was prolonged by about threefold compared to the original aptamers (i.e., without the tail). We found that the attachment of a poly(dA) tail at the 3′ end caused an increase of the clotting inhibitory activity. A preliminary in vivo assay using BALB/c mice confirmed a considerably elongated clotting time for the tailed aptamer. When the poly(dA) tail was attached to three other DNA aptamers, DNase resistance was increased, indicating that the present finding can be universally applied to increase stability of DNA aptamers.

100 项与 NapaJen Pharma, Inc. 相关的药物交易

登录后查看更多信息

100 项与 NapaJen Pharma, Inc. 相关的转化医学

登录后查看更多信息